Angina, Stable, Coronary Artery Disease
Conditions
Brief summary
This study is a multicenter, prospective, blinded (blinding of clinical evaluators), randomized controlled, event-driven non-inferiority clinical trial. Eligible subjects who meet the inclusion criteria will be registered in the central randomization system and randomized in a 1:1 ratio to either the experimental group (CT-FFR guided group) or the control group (QFR guided group).
Detailed description
This study is a multicenter, prospective, blinded, randomized controlled trial with event-driven non-inferiority design (blinding of clinical evaluators). A total of 4,648 participants will be recruited and randomly assigned to the CT-FFR guided group or the QFR guided group in a 1:1 ratio. Patients in the experimental group (CT-FFR guided group) will undergo three-dimensional reconstruction of coronary arteries and CT-FFR calculation using coronary CT angiography (CCTA) images and the RuiXin-FFR software. The CT-FFR results will be interpreted and analyzed by the researchers. If the CT-FFR value is \>0.8, patients will receive medical therapy only, while if the CT-FFR value is ≤0.8, patients will undergo further coronary angiography to determine the appropriate treatment strategy (PCI, CABG, or medical therapy), based on the anatomical features of the lesion and CT-FFR results. Patients in the control group (QFR guided group) will undergo invasive coronary angiography (ICA) and QFR calculation based on ICA images. If the QFR value is ≤0.8 and the lesion is suitable for intervention, patients will receive PCI, while if the QFR value is \>0.8, medical therapy will be recommended. Both groups will be followed up for clinical outcomes, health economics indicators, and quality of life at 1 month, 6 months, 1 year, 2 years, and 3 years. The occurrence of major adverse cardiovascular events (MACE) will be compared between the two groups. The study will also assess the effectiveness, safety, and economic value of CT-FFR in guiding diagnosis and treatment decisions for patients with stable angina, using QFR guided PCI as a control, with a non-inferiority comparison.
Interventions
DEVICECT-FFR
CT -FFR(coronary computed tomography angiography drived fractional flow reserve derived) uses routine coronary computed tomography angiography (CTA) images and applies a specific algorithm to extract both anatomical and physiological information of the coronary arteries. By combining these two pieces of information, a fluid dynamics model of the coronary arteries can be established, allowing the calculation of FFR at any location of the coronary arteries.
DEVICEQFR
Quantitative flow ratio (QFR) is a new method for evaluating the functional significance of coronary artery stenosis based on angiography. It can be used for real-time detection of hemodynamic abnormalities in the coronary arteries in the catheterization lab. Unlike traditional methods that require the use of pressure wires and vasodilators such as adenosine, the QFR examination process only requires routine coronary angiography. By reconstructing the three-dimensional structure of the blood vessels and analyzing the hemodynamics, the QFR can evaluate the fractional flow reserve (FFR) without the need for pressure wires and vasodilators.
Sponsors
Shanghai Zhongshan Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥18 years * with stable chest pain who underwent CCTA and have at least 1 lesion with a percent diameter stenosis (DS%) between 50% and 90% in a coronary artery with a ≥2.5 mm reference vessel diameter by visual assessment.These patients plan to undergo further non-invasive or invasive diagnosis and treatment. * Able to undergo invasive coronary angiography (ICA) * Capable of complying with the study procedures and fully understand the informed consent form approved by the ethics committee, and provide voluntary consent.
Exclusion criteria
General
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 1-year MACE | 1-year | Major Adverse Coronary Event (MACE) rates, defined as: 1. All cause death 2. myocardial infarction (MI) 3. Repeat myocardial revascularization 4. non-lethal stroke |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| repeat myocardial | 1-month, 6-month, 1-year, 2-years, 3-years | Repeat myocardial defined as:Planned revascularization,Unplanned revascularization |
| non-lethal stroke | 1-month, 6-month, 1-year, 2-years, 3-years | The American Heart Association/American Stroke Association (AHA/ASA) defines stroke as including the following types:CNS infarction,Ischemic stroke,Silent CNS infarction,Intracerebral hemorrhage,Subarachnoid hemorrhage,Cerebral venous thrombosis |
| The definite and probable stent thrombosis (defined by ARC-2 criteria) | 1-month, 6-month, 1-year, 2-years, 3-years | The definite and probable stent thrombosis (defined by ARC-2 criteria) including acute, subacute, late, and very late stent thrombosis within a specific time frame. |
| Proportion of non-obstructive CAD detected by ICA examination | 1-month, 6-month, 1-year, 2-years, 3-years | Proportion of non-obstructive CAD detected by ICA examination |
| Non-fatal myocardial infarction (MI) | 1-month, 6-month, 1-year, 2-years, 3-years | myocardial infarction (MI) defined as: Spontaneous myocardial infarction , perioperative myocardial infarction |
| All cause death | 1-month, 6-month, 1-year, 2-years, 3-years | All cause death defined as: Cardiovascular death, non-cardiovascular death, death of unknown cause |
| Health Economics Evaluation Endpoints | 1-month, 6-month, 1-year, 2-years, 3-years | Cost-effectiveness analysis, cost-utility analysis. The information collected by the cost indicators is as follows: 1. Costs associated with initial hospitalization, including: 2. Estimated cost of major cardiovascular medication 3. Total medical expenses related to major cardiac adverse events occurring during outpatient and/or hospitalization |
| Quality of life (QOL) | 1-month, 6-month, 1-year, 2-years, 3-years | Quality of life (QOL) will be assessed using the EQ-5D-VAS questionnaire. Angina status will be assessed using the Seattle Angina Questionnaire. |
| Cumulative radiation exposure | 1-month, 6-month, 1-year, 2-years, 3-years | Cumulative radiation exposure within1-month, 6-month, 1-year, 2-years and 3-years of study entry included all cardiovascular tests and invasive procedures, including CTA, myocardial perfusion imaging, and ICA. |
| MACE | 1-month, 6-month, 2-years, 3-years | Major Adverse Coronary Event (MACE) rates, defined as: 1. All cause death 2. myocardial infarction (MI) 3. Repeat myocardial revascularization 4. non-lethal stroke |
Countries
China
Contacts
Primary Contactchenguang Li, doctor
Outcome results
None listed